Metformin Reduces the Progression of Atherogenesis by Regulating the Sestrin2-mTOR Pathway in Obese and Diabetic Rats
10.12997/jla.2023.12.3.290
- Author:
Saravanakumar SUNDARARAJAN
1
;
Isaivani JAYACHANDRAN
;
Gautam Kumar PANDEY
;
Saravanakumar VENKATESAN
;
Anusha RAJAGOPAL
;
Kuppan GOKULAKRISHNAN
;
Muthuswamy BALASUBRAMANYAM
;
Viswanathan MOHAN
;
Nagaraj MANICKAM
Author Information
1. Department of Vascular Biology, Madras Diabetes Research Foundation & ICMR Centre for Advanced Research on Diabetes, Chennai, India
- Publication Type:Original Article
- From:Journal of Lipid and Atherosclerosis
2023;12(3):290-306
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objective:In previous research, we found that Sestrin2 has a strong association with plasma atherogenicity and combats the progression of atherogenesis by regulating the AMPK-mTOR pathway. Metformin, an activator of AMPK, is widely used as a first-line therapy for diabetes, but its role in preventing atherosclerosis and cardiac outcomes is unclear. Hence, we aimed to assess the effect of metformin on preventing atherosclerosis and its regulatory role in the Sestrin2-AMPK -mTOR pathway in obese/diabetic rats.
Methods:Animals were fed a high-fat diet to induce obesity, administered streptozotocin to induce diabetes, and then treated with metformin (150 mg/kg body weight) for 14 weeks. Aorta and heart tissues were analyzed for Sestrin2 status by western blotting and immunohistochemistry, AMPK and mTOR activities were investigated using western blotting, and atherogenicity-related events were evaluated using reverse transcription quantitative polymerase chain reaction and histology.
Results:Obese and diabetic rats showed significant decrease in Sestrin2 levels and AMPK activity, accompanied by increased mTOR activity in the heart and aorta tissues. Metformin treatment significantly restored Sestrin2 and AMPK levels, reduced mTOR activity, and restored the altered expression of inflammatory markers and adhesion molecules in obese and diabetic rats to normal levels. A histological analysis of samples from obese and diabetic rats showed atherosclerotic lesions both in aorta and heart tissues. The metformin-treated rats showed a decrease in atherosclerotic lesions, cardiac hypertrophy, and cardiomyocyte degeneration.
Conclusion:This study presents further insights into the beneficial effects of metformin and its protective role against atherosclerosis through regulation of the Sestrin2-AMPK-mTOR pathway.
